About Gadeta
Gadeta is a Healthcare company based in Utrecht (Netherlands) founded in 2015, and was acquired by Clade in October 2023. T Cell based cancer therapies based on gamma delta (γδ) T cell receptors. Gadeta has raised $7.82 million across 2 funding rounds from investors including Clade TX, Kite Pharma and European Union. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Gadeta is focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs). It has developed a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta TCRs with an enhanced anti-cancer reactivity. Its new cell-based anti-cancer product called T Cells engineered to express a defined Gamma Delta TCR (TEGs) that has strong therapeutic potential for combating and eradicating both hematological and solid tumors. This approach utilizes high-affinity gamma delta TCRs expressed on αβ T cells with superior proliferation capacity. Its lead program is in acute myeloid leukemia (AML).
- Headquarters Utrecht, Netherlands
- Stage Acquired
- SectorsHealthcare
- Website gadeta.nl
- Acquired by Kite Pharma (Jul 2018)
Funding Insights of Gadeta
Gadeta has successfully raised a total of $7.82M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $320.63 thousand completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.82M
- Total Rounds 2
- Last Round Grant — $320,626
- First Round $7.82M
(Mar 2016)
- Investors Count 4
All 2 funding rounds of Gadeta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $320,626 | Grant | – | – | |
| Mar 2016 | $7.82M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in Gadeta
Gadeta has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Clade TX, Kite Pharma and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Knowledge transfer support is provided by Utrecht Holdings. | utrechtholdings.nl | Utrecht, Netherlands | ||
Early-stage life science focused VC firm investing in geographies such as Europe and the US | medicxi.com | London, United Kingdom | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Developer of therapies for orphan diseases and other disease conditions | 2015 | baxalta.com | Chicago, United States | |
Cancer immunotherapy products are developed using genetic engineering. | 2009 | kitepharma.com | Los Angeles, United States | |
Stem cell-derived therapies for cancer are developed using pluripotent cells. | 2020 | cladetx.com | Cambridge, United States |
Investor details for Gadeta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Gadeta
3 people are tracked at Gadeta (1 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Thijs van Montfort | Associate Director | Leadership |
Olga Surovtseva | Facilitair manager | Team |
Telma Palma | Clinical Research Associate | Team |
Complete people profiles for Gadeta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Gadeta
5 dated milestones of Gadeta across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Gadeta is founded.
- Funding First funding round of $7.8M.
- Exit Acquired by Kite Pharma.
- Funding Latest funding round, Grant, of $321K.
- Exit Acquired by Clade.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gadeta
Complete news archive for Gadeta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gadeta
Gadeta was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Gadeta is headquartered in Utrecht, Netherlands.
Gadeta is a funded company, having raised a total of $7.82M across 2 funding rounds to date. The company's 1st funding round was a Series A of $7.82M, raised on Mar 2016.
Gadeta is focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs). It has developed a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta TCRs with an enhanced anti-cancer reactivity. Its new cell-based anti-cancer product called T Cells engineered to express a defined Gamma Delta TCR (TEGs) that has strong therapeutic potential for combating and eradicating both hematological and solid tumors. This approach utilizes high-affinity gamma delta TCRs expressed on αβ T cells with superior proliferation capacity. Its lead program is in acute myeloid leukemia (AML).
Gadeta has 6 investors. Key investors include Clade TX, Kite Pharma, European Union, Baxalta, and Utrecht Holdings.
Yes. Gadeta was acquired by Kite Pharma in July 2018.